setrusumab
DrugIntravenous infusion
Other names: BPS804
NCT Number: NCT03118570
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Mereo Investigator Site, Toronto, Ontario, Canada
This study was previously posted by Mereo Biopharma and was transferred to Ultragenyx in February 2021.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous infusion
Other names: BPS804
tablets
capsules
Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
Time frame: Baseline, Month 12 (end of treatment [EOT])
Assessed by high resolution peripheral quantitative computed tomography (HRpQCT). HRpQCT scans were performed on the participant's distal non-dominant arm. In cases of an arm that had been supported with rods or had significant deformity, the dominant limb was selected. Data presents the ratio of the means between the visit and Baseline from analysis of covariance (ANCOVA).
Time frame: Baseline, Month 12 (EOT)
Assessed by finite element analysis (FEA) of models generated from HRpQCT images of the distal radius.
Time frame: Baseline, Month 12 (EOT)
Assessed by FEA of models generated from HRpQCT images of the distal radius.
Time frame: Baseline, Months 6, 12 (EOT), 18, 24
Assessed by HRpQCT. HRpQCT scans were performed on the participant's distal non-dominant arm. In cases of an arm that had been supported with rods or had significant deformity, the dominant limb was selected. Data presented is the ratio of the means between the Visit and Baseline from ANCOVA.
Time frame: Baseline, Months 6, 12 (EOT)
Assessed by HRpQCT. HRpQCT scans were performed on the participant's distal non-dominant arm. In cases of an arm that had been supported with rods or had significant deformity, the dominant limb was selected. Data presented is the ratio of the means between the Visit and Baseline from ANCOVA.
Time frame: Baseline, Months 6, 12 (EOT), 18, 24
Assessed by FEA of models generated from HRpQCT images of the distal radius.
Time frame: Baseline, Months 6, 12 (EOT)
Assessed by FEA of models generated from HRpQCT images of the distal radius.
Time frame: Baseline, Months 6, 12 (EOT), 18, 24
Assessed by FEA of models generated from HRpQCT images of the distal radius.
Time frame: Baseline, Months 6, 12 (EOT)
Assessed by FEA of models generated from HRpQCT images of the distal radius.
Time frame: Month 12 (EOT)
Fracture assessment, confirmed by central radiographic reading, was carried out for peripheral including all major long bones, minor bone (digits, ribs) and vertebral fractures. Fractures without clinical symptoms, detected only by means of radiographic investigations, were not included in the analysis.
Time frame: Baseline, Month 6
BMD was evaluated by dual-energy x-ray absorptiometry (DXA). T-Score was calculated based on actual measured bone density value. T-scores are standardized scores that reflect the standard deviations (SDs) above/below the normal mean for young adults. A score of 50 indicates the population mean with a standard deviation of 10. A positive change in DXA T-score indicates an improvement in BMD.
Time frame: Baseline, Month 6
BMD was evaluated by DXA.
Time frame: Baseline, Month 12 (EOT)
BMD was evaluated by DXA. T-Score was calculated based on actual measured bone density value. T-scores are standardized scores that reflect the standard deviations (SDs) above/below the normal mean for young adults. A score of 50 indicates the population mean with a standard deviation of 10. A positive change in DXA T-score indicates an improvement in BMD.
Time frame: Baseline, Month 12 (EOT)
BMD was evaluated by DXA.
Time frame: Baseline, Months 6, 12 (EOT), 18, and 24
Assessed by HRpQCT. HRpQCT scans were performed on the participant's distal non-dominant arm. In cases of an arm that had been supported with rods or had significant deformity, the dominant limb was selected. Data presented is the ratio of the means between the Visit and Baseline from ANCOVA.
Time frame: Baseline, Months 6, 12 (EOT), 18, and 24
Assessed by HRpQCT. HRpQCT scans were performed on the participant's distal non-dominant arm. In cases of an arm that had been supported with rods or had significant deformity, the dominant limb was selected. Data presented is the ratio of the means between the Visit and Baseline from ANCOVA.
Time frame: Baseline, Month 6, Month 12 (EOT)
Time frame: Baseline, Months 6, 12 (EOT)
Lean and fat body mass was evaluated using whole body DXA (including the head).
Time frame: Baseline, Months 1, 3, 6, 9, 12 (EOT)
Time frame: Baseline, Months 1, 3, 6, 9, 12 (EOT)
Time frame: Baseline, Months 6, 12 (EOT)
The SF-12 is a generic, 12-item survey that measures 8 domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. It yields scale scores for each of these 8 domains and 2 summary measures of physical and mental health: The Physical Component Summary and the Mental Component Summary. The total score for the Physical Component Summary ranges from 0 to 100, where higher scores reflect better physical functioning.
Time frame: Baseline, Months 6, 12 (EOT)
The SF-12 is a generic, 12-item survey that measures 8 domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. It yields scale scores for each of these 8 domains and 2 summary measures of physical and mental health: The Physical Component Summary and the Mental Component Summary. The total score for the Mental Component Summary ranges from 0 to 100, where higher scores reflect better mental health functioning.
Time frame: Baseline, Months 6 and 12 (EOT)
The EQ-5D-5L is a standardised measure of health status comprised of a descriptive system of 5 health-related quality of life states (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a Visual Analogue Scale (VAS) of overall health. Each dimension is rated on a 5-point response scale indicating severity of problems, where 1 is "no problems" and 5 is "extreme problems". The 5 questions are scored and together contribute to the EQ-5D index (utility) score between 0 and 1 (1 being perfect health).
Time frame: Baseline, Months 6, 12 (EOT)
The OIQoL-A measures 5 areas of quality of life related to OI (Physical Function, Pain, Hearing Loss, Taking Care/Concerns, Social and Family Life and Activities). The total score is calculated on a 0-100 scale, where higher scores indicate a greater (negative) impact on quality of life.
Time frame: Baseline, Months 6, 12 (EOT)
The OIQoL-A measures 5 areas of quality of life related to OI (Physical Function, Pain, Hearing Loss, Taking Care/Concerns, Social and Family Life and Activities). The Pain subscale ranges from 0 to 10, with higher value representing worse pain.
Time frame: Baseline, Months 6, 12 (EOT)
The OIQoL-A measures 5 areas of quality of life related to OI (Physical Function, Pain, Hearing Loss, Taking Care/Concerns, Social and Family Life and Activities). The Activities subscale ranges from 0 to 100, with higher value representing increased difficulty.
Time frame: up to Month 14
Serum samples were screened for antibodies binding to setrusumab using a validated assay method by or under the supervision of the sponsor.
Time frame: Non-serious AEs: up to Month 14; Serious AEs: up to Month 24. (Average duration of exposure to placebo was 5 months and for setrusumab was 11 month plus follow-up to 24 months.)
An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; is another important medical event. The intensity for each AE was graded as mild, moderate or severe, according to the investigator's judgement. An event was considered related to study drug if there were a "reasonable possibility" of a relationship, according to the investigator's clinical judgment. A TEAE was defined as an event occurring or worsening on or after the first dose of study medication.
Ultragenyx Pharmaceutical Inc
Industry
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
Acronym: Asteroid
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07478224
Behavior, Bone Diseases
Ghent, Belgium
View Trial DetailsNCT01061099
Bone Diseases, Bone Diseases, Developmental
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05559801
Bone Diseases, Bone Diseases, Developmental
View Trial DetailsNCT00076830
Bone Diseases, Bone Diseases, Developmental
Bethesda, Maryland, United States
View Trial Details